What is the current stock price of Edesa Biotech, Inc. (EDSA)?

As of the latest market data, Edesa Biotech, Inc. (EDSA) is trading at $5.52. The stock has seen a loss of -6.76% today.

Does Edesa Biotech, Inc. (EDSA) pay a dividend?

Based on current data, Edesa Biotech, Inc. does not have a confirmed active dividend policy.

What is the market cap of Edesa Biotech, Inc.?

The current market capitalization of Edesa Biotech, Inc. (EDSA) is approximately unavailable.

EDSA

Edesa Biotech, Inc.·Healthcare

5.52

6.757%(−0.40)

Market Closed

6.15

11.413%(+0.63)

After Hours

Last Updated: — ET

52W L: $0.7252W H: $9.37

EDSA NEWS

globenewswire.com

Mar 31

Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit

Selection Follows Positive Phase 3 Results for Paridiprubart Demonstrating Statistically Significant Mortality Reductions in ARDS Patients Selection Follows Positive Phase 3 Results for Paridiprubart Demonstrating Statistically Significant Mortality Reductions in ARDS Patients

globenewswire.com

Mar 26

Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment

TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today provided an update on preparations and reaffirmed enrollment timeline guidance for its Phase 2 clinical study of EB06 in moderate-to-severe nonsegmental vitiligo. The announcement coincides with the company's sponsorship and participation today at the Global Vitiligo Foundation (GVF) Annual Scientific Symposium in Denver, Colorado.

globenewswire.com

Feb 24

Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study

TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today positive additional data from a Phase 3 study of paridiprubart.

gurufocus.com

Feb 13

Market Today: AI Fears Rattle Stocks; CPI Cools, Rivian Pops

Guru Stock PicksRobert Bruce has made the following transactions:Reduce in NEE by 1.49%Ray Dalio has made the following transactions:Reduce in CNX by 13.43%Sold

globenewswire.com

Feb 13

Edesa Biotech Reports Fiscal 1st Quarter 2026 Results

TORONTO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three months ended December 31, 2025 and provided an update on its business.

Company Profile

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2010-06-21

Beta

-0.68

Websitewww.edesabiotech.com↗